Table 4 Adverse events of MC categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.

From: Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept

 

Any grade N patients (%)

Grade 1–2

N patients (%)

Grade 3–4N patients (%)

Overall

12 (34.3%)

8 (22.8%)

2 (5.7%)

Fatigue

6 (17.1%)

6 (17.1%)

0

Hand-Foot skin reaction

3 (8.5%)

2 (5.7%)

1 (2.9%)

Thrombocytopenia

3 (8.5%)

1 (2.9%)

2 (5.7%)

Neutropenia

2 (5.7%)

2 (5.7%)

0

Anaemia

1 (2.9%)

1 (2.9%)

0

Bilirubin elevation

1 (2.9%)

1 (2.9%)

0

Nausea/Vomiting

1 (2.9%)

1 (2.9%)

0

Mucositis

1 (2.9%)

1 (2.9%)

0

Back to article page